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counted at 5% per year. Deterministic and probabilistic sensitivity analyses (PSA) were 
performed to test the model robustness. RESULTS: Using clinical results of patients 
previously treated with a calcium-based binder, for the ITT population, the ICERs 
were $24,724/QALY, $15,053/LYS and $6,700/additional success (i.e., SP goal 
achievement), respectively. For patients who completed the randomized controlled 
trial, the ICERs of LC compared with SH were $15,285/QALY, $9,337/LYS and 
$8,265/additional success respectively. The PSAs indicated a 61.9% and 85.8% prob-
ability of LC being cost-effective at the $50,000/QALY threshold, for the ITT popula-
tion and completer populations, respectively. Sensitivity analyses support the 
robustness of the model results. CONCLUSIONS: LC is a cost-effective strategy 
compared to SH in ESRD patients previously treated with calcium-based binders.
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OBJECTIVES: The calcineurin inhibitor (CNI) based regimens have improved short-
term patient and graft survival. However, the nephrotoxicity of CNI has limited the 
long-term improvement of outcomes. Recently, sirolimus, a novel class of immunosup-
pressant, got an approval in Korea. In this report, the cost-effectiveness of sirolimus 
based regimen compared with CNI based regimens was evaluated especially in the 
lower immunological risk renal transplant patients under Korea health care system. 
METHODS: A Markov model was developed to simulate costs and outcomes of a 
renal transplant recipient for 20 years with 5% discount rate in the societal perspec-
tive. Health states were deﬁ ned as patient with graft survival, patient with graft failure, 
patient with regraft survival, patient with regraft failure and patient death. Quality 
adjusted life-years (QALYs) were taken as effectiveness parameter. Efﬁ cacy data were 
obtained from systematic review of immunosuppressive regimens in lower immuno-
logical risk renal transplant recipients. And the additional beneﬁ ts of mTOR inhibitor 
(including sirolimus), reduced nephrotoxicity and lower relative risk to the incidence 
of malignancy, were reﬂ ected in the model. Utility weights were obtained from pub-
lished literature. Costs were calculated by the Korean public institutional data and 
clinical expert opinions. Sensitivity analyses were performed on crucial parameters. 
RESULTS: Sirolimus based regimen costs KRW 130,067,696 for the 8.94QALYs for 
20 years treatment duration, whereas KRW 140,185,240 for 8.67 QALYs for tacro-
limus based regimen, and KRW 131,136,664 for 8.56 QALYs for cyclosporine based 
regimen. Sirolimus based regimen was shown to be dominant over the others, as it 
was more efﬁ cacious in QALYs and less costly. The sensitivity analysis showed that 
the results were quite robust across most parameters. CONCLUSIONS: Sirolimus 
based regimen is expected to be superior in the clinical effectiveness and cost-saving 
in lower risk renal transplant recipients compared with the most frequently prescribed 
CNI regimens in Korea.
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OBJECTIVES: Diabetic nephropathy is a serious and common complication in dia-
betic patients; however the onset and the course can be favourably inﬂ uenced by 
appropriate therapy when detected early. Current recommendations include testing of 
creatinine based estimation of glomerular ﬁ ltration rate (eGFR) and for microalbu-
minuria. Due to substantial limitations of creatinine, cystatin C (cysC) has been 
proposed as alternative marker for early detection of (chronic kidney disease) CKD. 
METHODS: We developed a Cost-Utility Model to simulate the long-term conse-
quences and disease progression for diabetic patients using serum cysC instead of 
Creatinine for monitoring of kidney function. Markov modelling techniques were used 
to estimate incidence of complications and disease progression, and Monte Carlo 
simulation accounted for uncertainty. The model includes 11 health states to describe 
the disease progression and occurrence of adverse events. Probabilities were derived 
from clinical and epidemiological studies. The cohort deﬁ nition was adapted from the 
UKPDS study. Direct medical costs from published sources were used and expressed 
in 2009 Euro from the payer’s perspective. QALYs and total costs were projected over 
a life-time horizon and discounted at 5% p.a. RESULTS: Early detection of CKD with 
cysC leads to lifetime costs of c52,950 and 14.19 QALYs (c3,732 per QALY). Detec-
tion with Creatinine amounts to c64,912 and 12.82 QALYs (c5,063 per QALY). Cost 
saving amounts to c11,962 per patient and a QALY gain of 1.37; these arise due to 
slower disease progression and reduced complications. The cumulative incidence of 
complications was estimated to be lower for cysC than Creatinine (−15%). Early 
detection with cysC leads to a decreased number of patient-years (14%-points) spent 
in ESRD, due to a later onset. Probabilistic sensitivity analyses demonstrated the 
robustness of the model. CONCLUSIONS: The economic beneﬁ t of using cysC is 
substantial, due to reduction in complications and disease progression as well as lower 
long-term costs.
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OBJECTIVES: Major controversy exists regarding the optimal treatment strategy in 
Acute Kidney Injury (AKI). The purpose of this study was to assess the incremental 
cost-effectiveness of continuous (CRRT) versus intermittent renal replacement therapy 
(IRRT) and conservative (CONS) AKI treatment in Belgium. METHODS: An area 
under the curve model was used, whereby patients are simulated using time-to-event 
data (survival analysis), combined with daily direct medical costs. Data were derived 
from the multi-centre SHARF4 study in which the three treatment modalities for AKI 
were compared. a time horizon of 2 years, starting from the admission to the hospital, 
was considered. Utility data were obtained from SF-36 assessment at 2 years and from 
literature data on in-hospital utility. RESULTS: Analyses indicated that mortality 
rates, cost and length of stay differed signiﬁ cantly between treatment mode during 
hospitalization. The mortality rate and the cost per day during the post-discharge 
follow-up period showed no signiﬁ cant difference between the treatment modes. 
Utility values, which improved gradually after admission to the hospital, revealed no 
signiﬁ cant differences between the three treatment strategies. Conservative treatment 
was associated with a 2-year cost of c34,090 and 0.49 QALYs. The CRRT was the 
most expensive therapy with a cost of c51,664 leading to 0.52 QALYs. The cost and 
QALYs associated with IRRT were c43,711 and 0.46. The ICER of CRRT versus 
IRRT was c131,604/QALY, while the ICER of CRRT versus CONS amounted to 
c651,318/QALY. Additionally the conservative treatment dominated IRRT. Sensitiv-
ity analysis—tornado diagram—conﬁ rmed the robustness of the results. CONCLU-
SIONS: This study has indicated that the most expensive treatment (CRRT) associated 
with an incremental cost of approximately c7952 generates only a minor increase in 
QALYs of 0.06 compared to IRRT. Additionally the results revealed that IRRT was 
dominated by CONS. From a health economic perspective conservative therapy seems 
to be the preferred treatment strategy.
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OBJECTIVES: A probabilistic patient-level Markov model was developed to simulate 
lifetime clinical and economic outcomes of the cinacalcet treatment in secondary 
hyperparathyroidism (SHPT) patients. We present the adaptation of this model to ﬁ ve 
European countries: Italy, Spain, Portugal, Czech Republic and Switzerland. 
METHODS: In the simulation the treatment with cinacalcet inﬂ uences the trend in 
time of individual parathyroid hormone (PTH), serum calcium (Ca) and phosphorous 
(P) levels, based on the OPTIMA study. Published correlations between these levels, 
mortality and morbidity (CV events, fractures, and parathyroidectomies) were incor-
porated as well as local epidemiologic and cost data for dialysis, drugs and events 
management. Simulation horizon was patient lifetime; standard treatment (vitamin D 
sterols and phosphate binders) and cinacalcet plus standard treatment were compared. 
The effectiveness was measured as life expectancy (LE) and quality-adjusted life 
expectancy (QALE). Health Utility Indexes derived from literature and took into 
account dialysis, CV events and fractures. RESULTS: The simulated mean LE exten-
sion was 1.20 life-years (LY) in Italy, 1.1 LY in Spain, 1.18 LY in Portugal, 1.10 LY 
in Czech Republic and 1.40 LY in Switzerland. QALE increase was 0.89, 0.82, 0.89, 
0.80 and 1.01 quality-adjusted life-years (QALY) in the same countries, respectively. 
The lifetime average cost increase, calculated not taking into account the cost for 
dialysis, was c28,161 in Italy, c23,878 in Spain, c27,932 in Portugal, CZK 836,914 
(corresponding to c32,751) in Czech Republic and CHF 48,908 (c34,630) in Switzer-
land. The incremental cost-effectiveness ratio (ICER) was c23,473/LY and c31,616/
QALY in Italy, c21,789/LY and c29,270/QALY in Spain, c23,680/LY and c31,249/
QALY in Portugal, CZK 759,600/LY (approx. c29,726/LY) and CZK 1,042,643/
QALY (approx. c40,802/QALY) in Czech Republic and CHF 34,858/LY (approx. 
c24,682/LY) and CHF 48,310/QALY (approx. c34,207/QALY) in Switzerland. CON-
CLUSIONS: Cinacalcet treatment could be considered a cost-effective treatment of 
SHPT in all the countries analyzed. Results seem more homogeneous in the three 
southern countries.
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OBJECTIVES: Pharmacological interventions that are of beneﬁ t in non-dialysis popu-
lations have thus far been disappointing in dialysis patients. Since clinical trials are 
expensive and time-consuming, adjunct strategies are needed to support decision 
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making in prioritization of tracks for drug development. Genetic association studies 
may provide such a strategy when a genotype is associated with a well-deﬁ ned molecu-
lar and functional phenotype. Previously an association with better survival was found 
in incident dialysis patients with systemic inﬂ ammation and a deletion variant of the 
CC-chemokine receptor 5 (CCR5Δ32). Thus, we hypothesized that pharmacological 
CCR5 blockade could protect against inﬂ ammation associated mortality and esti-
mated if such a treatment would be cost-effective. METHODS: Ascreen-and-treat 
strategy was modelled in which patients were screened for the CCR5Δ32 polymor-
phism and patients with the wild-type genotype and high inﬂ ammation status were 
treated with CCR5 antagonists. a decision-analytic Markov model was used. Costs, 
utilities and clinical data on the association between CCR5 polymorphisms and 
mortality were all gathered from a single prospectively followed dialysis cohort 
(NECOSAD, n = 413). Univariate and probabilistic sensitivity analyses were per-
formed. RESULTS: Pharmacological CCR5 blockade in patients with CCR5 wild-type 
and high inﬂ ammation status decreased mortality (RR = 0.61) and improved the 
probability of renal transplantation (RR = 2.41). The cost-effectiveness of the screen-
and-treat strategy was c18,557 per life-year gained and c21,896 per quality-adjusted 
life-year (QALY) gained. The main drivers of the cost-effectiveness were the costs of 
pharmacological CCR5 blockade and the reduction in relative risk of mortality. 
Threshold analyses were performed for these two parameters. CONCLUSIONS: Phar-
macological blockade of the CCR5 receptor in inﬂ amed dialysis patients can be 
incorporated in a potential cost-effective genetic screen-and-treat program. This study 
illustrates the potential of genetic association studies in drug-development programs, 
as a new source of Mendelian randomized evidence from an observational setting.
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OBJECTIVES: A long-standing controversy in health-economics is whether future 
unrelated costs should be included in cost-effectiveness analyses. This discussion is 
relevant in Chronic Kidney Disease (CKD) for treatments that delay progression 
towards dialysis and prolong survival. In this study, we determined the inﬂ uence of 
future unrelated costs on the cost-effectiveness of the non-calcium based phosphate 
binder lanthanum carbonate (LC) when used as second-line treatment for hyperphos-
phatemia in predialysis patients. METHODS: Time-dependent Markov models were 
constructed; cohorts of 1000 patients were followed lifelong. Patients not reaching 
target serum phosphate (SP) levels on ﬁ rst-line calcium based phosphate binders (CB) 
were treated with LC. This strategy was compared with continued CB treatment. 
Patient-level data were pooled from two clinical trials, one in predialysis and one in 
dialysis. Reductions in SP levels delayed progression towards dialysis and prolonged 
survival. RESULTS: For the predialysis cohort, 544 did not achieve target SP levels 
(<4.6 mg/dl) on CB treatment, and 230 were eligible for LC treatment. Of these, 43 
(18.8%) now responded to an 8 week trial of LC. Compared with continued CB 
treatment, 150 life-years and 101 QALYs were gained with LC. Considerable future 
unrelated costs were accrued due to prolonged survival while on dialysis. Including 
these unrelated costs, the cost-effectiveness of second-line LC treatment was £17,150/
QALY. Excluding future unrelated costs, net health care cost-savings were estimated 
due to delayed progression towards dialysis. The net monetary beneﬁ t of LC treatment 
rose from £1302 to £4558 upon exclusion of future unrelated costs. CONCLUSIONS: 
Second-line treatment of hyperphosphatemia with LC in predialysis CKD patients is 
cost-effective irrespective of whether future unrelated costs are included. However, 
this analysis demonstrates the substantial impact of these costs on the cost-effective-
ness ratio. We recommend cost-effectiveness guidelines used for reimbursement pur-
poses should specify exclusion of future unrelated costs in the base case, with inclusion 
in sensitivity analysis.
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BACKGROUND: Governments across Europe are increasingly focused on controlling 
rising health care costs. Within this context, a major challenge for hemodialysis centres 
is to maximise efﬁ ciencies while maintaining high standards of care. OBJECTIVES: 
The aim of this study was to document health care personnel time for anaemia man-
agement in maintenance therapy for both shorter-acting erythropoiesis-stimulating 
agents (ESA) and a continuous erythropoiesis receptor activator (C.E.R.A.) once 
monthly (Q4W), and model time savings following the introduction of Q4W C.E.R.A. 
in ﬁ ve European countries. METHODS: A multinational, multicentre time and motion 
study has been conducted in 16 centres across Germany, France, Italy, Poland and 
Spain. The time spent on frequent anaemia management-related tasks (preparation, 
distribution, injection, record-keeping) was recorded in each centre by trained observ-
ers. Time/pt/session was used to calculate time/pt/year, time/centre/year and for model-
ling potential time savings with a 100% uptake of C.E.R.A. RESULTS: Numbers of 
ESA injections/pt/year, weighted by type of ESA, frequency and route of administra-
tion, ranged from 53–148. The mean uptake of C.E.R.A. Q4W across 16 centres was 
29% (7–56%). The mean annual reduction in the number of ESA administrations 
following conversion to C.E.R.A. was 76 (41–136). Estimated observed time/pt/year 
ranged from 38–310 min for ESA and 6–68 min for C.E.R.A. Assuming a 100% 
uptake of Q4W C.E.R.A. maintenance therapy, annual time savings/centre for fre-
quent anaemia management tasks would be 84% (79–91%) in Germany, 78% (74–
86%) in France, 88% (87–88%) in Italy, 85% (78–88%) in Poland and 77% 
(69–84%) in Spain. CONCLUSIONS: Substantial annual time savings on frequent 
anaemia management-related tasks were consistently found in hemodialysis centres 
across ﬁ ve European countries with a 100% uptake of Q4W C.E.R.A. maintenance 
therapy. This provides the opportunity to re-focus health care resources, at a critical 
time point in the dialysis procedure, on other important CKD care tasks in order to 
improve overall pt care.
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OBJECTIVES: There is a paucity of information available regarding the prevalence 
of post-transplant events and resource utilization associated with such events in renal 
transplant patients in real-life treatment settings. The PORTRAIT study aims to 
describe the health care resources used and to estimate the cost of managing post-
transplant patients using observational data from transplant databases and physician 
questionnaires from transplant centres across Europe. This abstract describes the 
preliminary results from a single UK centre. METHODS: A pilot retrospective obser-
vational study was undertaken in which resource usage over a three year period, 
calculated from Healthcare Resource Groups (HRGs), was employed to derive costs, 
with results stratiﬁ ed by glomerular ﬁ ltration rate (GFR) status at one year post 
transplant. Comparison of costs was undertaken using the non-parametric Mann-
Whitney test. RESULTS: There were 879 renal transplant patients who had a recorded 
GFR measurement at one year post transplant. Overall 130 (14.8%) had a GFR of 
<30 mL/min/1.73 m2; 535 (60.1%) had a GFR between >30 and ≤60 mL/min/1.73 m2 
and 214 (24.3%) had a GFR > 60 mL/min/1.73 m2. Overall three-year HRG derived 
costs were signiﬁ cantly lower in the >60 mL/min/1.73 m2 group at £497 (SD = £111) 
compared to both the 30–60 and <30 mL/min/1.73 m2, at £1,323 (SD = £1245, p = 
0.025) and £1448 (SD = 1726, p = 0.01) respectively. CONCLUSIONS: This study 
provides evidence that post-transplant resource usage in a real-life treatment setting 
(assessed using HRG tariffs) is approximately three times higher in those patients with 
lower post transplant GFR. Therefore management strategies that promote renal 
function post transplant are likely to provide important resource savings. An ongoing 
database and physician questionnaire study has been implemented to conﬁ rm these 
observations using a bottom-up costing approach. 
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: Little data is available describing the relationship between quality of 
life and levels of kidney function in renal transplant patients. We sought to assess the 
relationship between health utility and renal impairment in US and UK kidney trans-
plant (KTX) recipients. METHODS: Data was obtained from KTX patients enrolled 
at the kidney transplant facilities of the Renal Unit at the Cardiff and Wales NHS 
Trust in Cardiff, UK (n = 209) and Saint Louis University Hospital, St. Louis, MO (n 
= 233). General linear models were used to estimate adjusted EQ-5D means across 
CKD stages (K/DOQI classiﬁ cation). Partial Spearman’s correlation was used to evalu-
ate trend across CKD classes. We adjusted all models for age, gender, time since 
transplant and diagnosis of diabetes. We adjusted for center effect by including the 
variable indicating the center of enrollment and the appropriate interaction term in 
the model. RESULTS: Mean age of KTX recipients was 52.7 and 49.1 years and mean 
time since transplant was 5.6 and 3.3 years in the UK and US cohorts respectively. 
After adjustment, EQ-5D scores resulted as follows in UK and US samples respectively: 
CKD 1–2, 0.74 and 0.87; CKD 3, 0.69 and 0.88, CKD 4, 0.61 and 0.82; CKD 5, 
0.39 and 0.79. The trend across CKD classes was statistically signiﬁ cant in both 
samples (UK: ρ = −0.24, P < 0.01; US: ρ = −0.19, p = 0.03). Center effect was statisti-
cally signiﬁ cant and mainly explained by inclusion of recipients with failed graft on 
dialysis in the UK sample. CONCLUSIONS: This study demonstrates a signiﬁ cant and 
independent relationship between levels of post transplant renal impairment and 
health utility. Management strategies that maximize post transplant renal function 
will have important implications for patients’ quality of life.
